You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

GlaxoSmithKline in takeover bid for Human Genome Sciences

LONDON - GlaxoSmithKline PLC has made an offer to take over US drug maker Human Genome Sciences Inc. that values the company at nearly $2.6 billion.

GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, said Wednesday it is offering $13 cash per share for the company. A private offer last month by GSK at the same price was rejected by HGS management.

Continue reading below

HGS shares closed at $14.39 Tuesday on the Nasdaq exchange.

The tender offer, which is a direct approach to the target’s shareholders, will remain open for 20 days.

Human Genome Sciences, based in Rockville, Md., has a 50-50 profit sharing agreement with GSK on the lupus drug Benlysta, which won regulatory approval in the United States and Europe last year.

The two companies are also cooperating in late-stage development of darapladib, for the treatment of cardiovascular disease, and albiglutide, for type 2 diabetes.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week